抗胆固醇药物,执行功能,以及唐氏综合征的认知/行为变化
Nancy Raitano Lee1, Goldie A McQuaid2, Haila Jiddou1
1Department of Psychological and Brain Sciences, Drexel University, Philadelphia, Pennsylvania, USA.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|October 13, 2025
概括
抗胆固醇 (AC) 药物使用可能会使唐氏综合征 (DS) 的年轻成人认知挑战恶化. 这突出了DS患者认知能力下降的潜在可修改的风险因素.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 遗传学 遗传学 是一个
背景情况:
- 抗胆固醇 (AC) 药物是一般人群认知障碍的已知危险因素.
- 唐氏综合征 (DS) 与痴呆症的高患病率有关.
- 抗逆转基因药物对DS患者认知的影响以前没有被研究过.
研究的目的:
- 调查抗胆固醇药物使用与患有唐氏综合征的年轻成年人的认知功能之间的关联.
- 为了确定潜在的可修改的认知恶化风险因素在DS人口.
主要方法:
- 一项涉及108名患有DS的年轻成年人 (18-39岁) 的研究.
- 家庭成员报告了使用痴呆症查仪的药物使用,执行功能和认知/行为变化.
- 使用CRIDECO抗胆固醇负载量表 (CALS) 评估药物的抗胆固醇功效.
主要成果:
- 40%的参与者使用至少一种药物,其CALS AC强度≥1.1.
- 服用AC药物的个人表现出更大的执行功能困难.
- 与非使用者相比,这些人也显示出更多的认知和行为变化报告.
结论:
- 抗胆固醇药物使用可能是唐氏综合征成人认知能力下降的可修改风险因素.
- 需要进一步的研究,特别是包括患有DS的老年人在内的纵向研究.
- 识别这些风险因素对于管理DS患者痴呆风险至关重要.
相关概念视频
Alzheimer's Disease: Treatment
822
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
822
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
1.4K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.4K
Parkinson's Disease: Treatment
983
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
983
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
558
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
558
Cholinergic Antagonists: Pharmacological Actions
1.6K
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
1.6K
Attention-Deficit/Hyperactivity Disorder
758
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
758


